|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK,
Jo HJ, Kim HS, Oh N, Song GA and Park DY: Snail and serpinA1
promote tumor progression and predict prognosis in colorectal
cancer. Oncotarget. 6:20312–20326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koerner J, Brunner T and Groettrup M:
Inhibition and deficiency of the immunoproteasome subunit LMP7
suppress the development and progression of colorectal carcinoma in
mice. Oncotarget. 8:50873–50888. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun X, Wang T, Zhang C, Ning K, Guan ZR,
Chen SX, Hong TT and Hua D: S100A16 is a prognostic marker for
colorectal cancer. J Surg Oncol. 117:275–283. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, et al: Annual report to the nation on the status of
cancer, 1975–2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening, and treatment) to reduce
future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bagaria B, Sood S, Sharma R and Lalwani S:
Comparative study of CEA and CA19-9 in esophageal, gastric and
colon cancers individually and in combination (ROC curve analysis).
Cancer Biol Med. 10:148–157. 2013.PubMed/NCBI
|
|
7
|
Tan E, Gouvas N, Nicholls RJ, Ziprin P,
Xynos E and Tekkis PP: Diagnostic precision of carcinoembryonic
antigen in the detection of recurrence of colorectal cancer. Surg
Oncol. 18:15–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flamini E, Mercatali L, Nanni O, Calistri
D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A,
Verdecchia GM, et al: Free DNA and carcinoembryonic antigen serum
levels: An important combination for diagnosis of colorectal
cancer. Clin Cancer Res. 12:6985–6988. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartolmäs T, Hirschfeld-Ihlow C, Jonas S,
Schaefer M and Gessner R: LI-cadherin cis-dimerizes in the plasma
membrane Ca (2+) independently and forms highly dynamic
trans-contacts. Cell Mol Life Sci. 69:3851–3862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gessner R and Tauber R: Intestinal cell
adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci.
915:136–143. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ordóñez NG: Cadherin 17 is a novel
diagnostic marker for adenocarcinomas of the digestive system. Adv
Anat Pathol. 21:131–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Snow AN, Mangray S, Lu S, Clubwala R, Li
J, Resnick MB and Yakirevich E: Expression of cadherin 17 in
well-differentiated neuroendocrine tumours. Histopathology.
66:1010–1021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao
H, Sun Q, Yan F, Yan C, Li H, et al: The hOGG1 Ser326Cys
polymorphism contributes to digestive system cancer susceptibility:
Evidence from 48 case-control studies. Tumour Biol. 36:1029–1038.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Romero-Cordoba SL, Salido-Guadarrama I,
Rodriguez- Dorantes M and Hidalgo-Miranda A: miRNA biogenesis:
Biological impact in the development of cancer. Cancer Biol Ther.
15:1444–1455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu
H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in
breast cancer by targeting the suppressor of cytokine signaling 1
gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Magrelli A, Azzalin G, Salvatore M,
Viganotti M, Tosto F, Colombo T, Devito R, Di Masi A, Antoccia A,
Lorenzetti S, et al: Altered microRNA expression patterns in
hepatoblastoma patients. Transl Oncol. 2:157–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao L, Tian Y, Zhao Z, Zhang L, He X and
Pei Y: Expression and clinical significance of miR-224 and miR-378e
in colorectal cancer tissues. Tianjin Med J. 8:737–739, 20113.
|
|
21
|
Tang R, Liang L, Luo D, Feng Z, Huang Q,
He R, Gan T, Yang L and Chen G: Downregulation of miR-30a is
associated with poor prognosis in lung cancer. Med Sci Monit.
21:2514–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alnabulsi A and Murray GI: Integrative
analysis of the colorectal cancer proteome: Potential clinical
impact. Expert Rev Proteomics. 13:917–927. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Z, Gao S, Wang D, Song D and Feng Y:
Colorectal cancer cells are resistant to anti-EGFR monoclonal
antibody through adapted autophagy. Am J Transl Res. 8:1190–1196.
2016.PubMed/NCBI
|
|
25
|
Dimofte G, Târcoveanu E, Taraşi M, Panait
C, Lozneanu G, Nicolescu S, Porumb V and Grigoraş O: Mean number of
lymph nodes in colonic cancer specimen: Possible quality control
index for surgical performance. Chirurgia (Bucur). 106:759–764.
2011.PubMed/NCBI
|
|
26
|
Stojkovic Lalosevic M, Stankovic S,
Stojkovic M, Markovic V, Dimitrijevic I, Lalosevic J, Petrovic J,
Brankovic M, Pavlovic Markovic A and Krivokapic Z: Can preoperative
CEA and CA19-9 serum concentrations suggest metastatic disease in
colorectal cancer patients? Hell J Nucl Med. 20:41–45.
2017.PubMed/NCBI
|
|
27
|
Li R, Yang HQ, Xi HL, Feng S and Qin RH:
Inhibition of CDH17 gene expression via RNA interference reduces
proliferation and apoptosis of human MKN28 gastric cancer cells.
Int J Oncol. 50:15–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu Q, Shen W, Zhou H, Dong W and Gao D:
Knockdown of LI-cadherin alters expression of matrix
metalloproteinase-2 and −9 and galectin-3. Mol Med Rep.
13:4469–4474. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bernhard OK, Greening DW, Barnes TW, Ji H
and Simpson RJ: Detection of cadherin-17 in human colon cancer
LIM1215 cell secretome and tumour xenograft-derived interstitial
fluid and plasma. Biochim Biophys Acta. 1834:2372–2379. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van der Wurff AA, Vermeulen SJ, van der
Linden EP, Mareel MM, Bosman FT and Arends JW: Patterns of alpha-
and beta-catenin and E-cadherin expression in colorectal adenomas
and carcinomas. J Pathol. 182:325–330. 1997. View Article : Google Scholar
|
|
32
|
Takamura M, Ichida T, Matsuda Y, Kobayashi
M, Yamagiwa S, Genda T, Shioji K, Hashimoto S, Nomoto M, Hatakeyama
K, et al: Reduced expression of liver-intestine cadherin is
associated with progression and lymph node metastasis of human
colorectal carcinoma. Cancer Lett. 212:253–259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Donnarumma E, Fiore D, Nappa M, Roscigno
G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C,
et al: Cancer-associated fibroblasts release exosomal microRNAs
that dictate an aggressive phenotype in breast cancer. Oncotarget.
8:19592–19608. 2017. View Article : Google Scholar : PubMed/NCBI
|
